SubscribeLogin
Published

San Diego’s Halozyme withdraws $2.1B Evotec bid, just one week after making offer

Summary by San Diego Union Tribune
San Diego biotech firm Halozyme Therapeutics is walking back its proposed $2.1 billion acquisition of Evotec, saying the German drugmaker doesn’t want to be bought. The local company announced Friday morning at 5:35 a.m. that it was withdrawing its bid to buy Evotec for about $11.52 per share. Halozyme’s change of plans comes only a week after the proposal was announced. Halozyme’s CEO, Helen Torley, explained in the latest announcement that the…
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

MedicalMedical
GermanyGermany
Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal